Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
4
×
boston blog main
life sciences
national blog main
avapritinib
blueprint medicines
boston top stories
eli lilly
san francisco blog main
san francisco top stories
biotech
cancer
clinical trials
deals
genentech
medullary thyroid cancer
national top stories
non-small cell lung cancer
pralsetinib
roche
selpercatinib
thyroid cancer
andrew berens
biontech
boehringer ingelheim
cancer drugs
capmatinib
cstone pharmaceuticals
curevac
deciphera pharmaceuticals
europe blog main
europe top stories
european medicines agency
fda
fisogatinib
flatiron health
gastrointestinal stromal tumor
gastrointestinal stromal tumors
gist
gleevec
What
cancer
4
×
approval
blueprint
drug
fda
medicines
latest
ret
address
announced
approves
bets
bio
candidate
carries
certain
chasing
comes
companies
currently
cut
date
deadly
deal
deciphera
designed
effective
enticed
evidence
filing
forms
genetic
gi
hasn’t
marketing
medicine
messenger
molecules
morning
mrna
Language
unset
Current search:
cancer
×
boston
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
6 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines